External organizationMSD Sharp & Dohme GmbH

Basic data

Name:

MSD Sharp & Dohme GmbH

Country:

Germany

Region/province:

Bayern

City:

München

URL:

https://www.msd.de/

Projects

MK 3475 - 669 – A Phase III Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2018 - 2021

MSD Sharp & Dohme GmbH

MK 3475-689 – A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

2018 - 2024

MSD Sharp & Dohme GmbH

MK-3475 Prot. 630

2019 - 2021

MSD Sharp & Dohme GmbH

MSD MK-3475-587-00

2018 - 2028

MSD Sharp & Dohme GmbH

Studie MK 3475-252

2016 - 2022

MSD Sharp & Dohme GmbH

Studie MK3475-716

2019 - 2029

MSD Sharp & Dohme GmbH

Help

will be deleted permanently. This cannot be undone.